ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers

Overview of attention for article published in Molecular Cancer Therapeutics, September 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

So far, Dimensions has found 61 publications that cite this research output.

Article in Frontiers in Oncology (May 2023)

Article in Chemical Reviews (May 2023)

Article in Pharmacology & Therapeutics (April 2023)